UNSPSC 51333412: Eltoprazine hydrochloride

This classification denotes a serotonin agonist with the molecular formula C12H16N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5275JY4PKD, chemically known as piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-, hydrochloride (1:1), but more generally known as eltoprazine hydrochloride, which bears US NIH Compound Identifier 3025067. European Medicines Agency schedules eltoprazine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06496MIG.

Most nations, for tariff purposes, schedule eltoprazine hydrochloride under HS 29349990. SMILES: C1CC(C2C(C1)OCCO2)N3CCNCC3.CL.

UNSPSC 51333412 Eltoprazine hydrochloride is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent state and local solicitations show little activity directly aligned with this specific active pharmaceutical ingredient. The code encompasses individual drug substances and formulations purchased for public health programs, emergency response, and community health initiatives. State and local buyers under this code include county health departments, state health and human services agencies, and regional cooperative purchasing alliances that aggregate pharmaceutical procurement across multiple jurisdictions. The scope of actual buying activity visible in recent opportunities extends beyond single-ingredient pharmaceuticals to broader pharmaceutical procurement programs including naloxone, generic multi-source drugs, and over-the-counter products distributed through authorized wholesaler networks.

Geographic activity appears concentrated in the Southeast and Upper Midwest. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, supporting community health initiatives with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription programs, signaling future formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities including Oregon, requiring products to be available by May 15, 2026, with contracts effective July 1, 2026. The MMCAP procurement weighted price competitiveness at 75 percent and required compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), with distribution through three authorized wholesalers and a 3 percent administrative fee structure.